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Patients with suspected common bile duct (CBD) stones are often diagnosed using endo-
scopic retrograde cholangiopancreatography (ERCP), an invasive procedure with risk of
significant complications. Using endoscopic ultrasound (EUS) or Magnetic Resonance
CholangioPancreatography (MRCP) first to detect CBD stones can reduce the risk of un-
necessary procedures, cut complications and may save costs.
Aim
This study sought to compare the cost-effectiveness of initial EUS or MRCP in patients with
suspected CBD stones.
Methods
This study is a model based cost-utility analysis estimating mean costs and quality-adjusted
life years (QALYs) per patient from the perspective of the UK National Health Service
(NHS) over a 1 year time horizon. A decision tree model was constructed and populated
with probabilities, outcomes and cost data from published sources, including one-way and
probabilistic sensitivity analyses.
Results
Using MRCP to select patients for ERCP was less costly than using EUS to select patients
or proceeding directly to ERCP ($1299 versus $1753 and $1781, respectively), with similar
QALYs accruing to each option (0.998, 0.998 and 0.997 for EUS, MRCP and direct ERCP,
respectively). Initial MRCP was the most cost-effective option with the highest monetary net
benefit, and this result was not sensitive to model parameters. MRCP had a 61% probability
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Health.of being cost-effective at $29,000, the maximum willingness to pay for a QALY commonly
used in the UK.
Conclusion
From the perspective of the UK NHS, MRCP was the most cost-effective test in the diagno-
sis of CBD stones.
Introduction
Patients with suspected common bile duct (CBD) stones are usually diagnosed using endoscop-
ic retrograde cholangiopancreatography (ERCP), which is considered to be the reference stan-
dard.[1] Using ERCP for CBD stone diagnosis means that stones can be removed during the
same procedure following endoscopic sphincterotomy (ES). ERCP is an invasive procedure,
which has a risk of major complications such as pancreatitis and cholangitis associated with
morbidity and mortality.[2] The prevalence of CBD stones among patients at risk or suspected
of having this problem is 14–68%,[3–20] indicating that 32–86% of these patients are unneces-
sarily undergoing a procedure with a risk of major complications.
Endoscopic ultrasound (EUS) and magnetic resonance cholangiopancreatography (MRCP)
can be used to identify patients likely to have CBD stones. Patients can then proceed to invasive
testing and treatment by ERCP. Unnecessary invasive testing can be avoided in patients who
on the basis of EUS or MRCP are unlikely to have CBD stones which may reduce the costs and
negative impact on patient health of invasive testing. However both tests incur costs and nei-
ther is 100% accurate.
A recent Cochrane Review found that use of EUS or MRCP prior to ERCP can potentially
reduce the rate of unnecessary invasive testing by 30–70%.[21] A review of the NHS Economic
Evaluations Database using the search term “bile duct” [31 August 2013] identified 24 studies
relating to cost-effectiveness.[22] Howard et al found MRCP was less costly and more effective
than ERCP in patients with abdominal pain and/or abnormal liver function tests at a prior
probability of CBD stones of <60%.[23] Kaltenthaler et al found that MRCP was less costly
and more effective than ERCP in patients with biliary tree obstruction.[24–25] Arguedas et al
found that in patients with acute biliary pancreatitis at probabilities of CBD stones of 45%
EUS was most cost-effective, and at probabilities >45% direct ERCP was most cost-effective.
[26] None of these evaluated EUS versus MRCP versus invasive testing with ERCP in patients
with suspected CBD stones. Hence the relative costs and benefits of EUS, MRCP and direct in-
vasive testing are unclear.
This study aimed to investigate the cost-effectiveness of EUS versus MRCP in patients with
suspected CBD stones.
Methods
This is a model-based cost-utility analysis to estimate the mean cost and outcome per patient
associated with EUS versus MRCP prior to ERCP compared with proceeding directly to ERCP
in patients with suspected CBD stones based on symptoms such as obstructive jaundice, pan-
creatitis, abnormal ultrasound or liver function tests. The outcome measure is quality-adjusted
life years (QALYs), which combine length and quality of life.[27] QALYs are the recommended
outcome for use in UK economic evaluations.
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Costs are calculated in 2011/12 UK£ and presented in US$ using an exchange rate of US$1 =
£0.69.[28] Since EUS or MRCP are unlikely to affect long term disease outcomes, a time hori-
zon of 12 months for costs and outcomes was considered to be appropriate and discounting of
costs and benefits unnecessary.
Model structure
The analysis uses a decision tree to describe the options compared (Fig. 1). This is a commonly
used approach in cost-effectiveness studies of healthcare programmes.[27] The decision tree
nodes are points where more than one event is possible. The branches are mutually exclusive
events following each node. Decision nodes (represented by squares) show the different op-
tions that might, in theory, be chosen by decision-makers (e.g., to choose EUS, MRCP or direct
ERCP). We are primarily interested in the comparison between EUS and MRCP, using direct
ERCP as a benchmark. Chance nodes (circles) show uncertain events, each of which is associat-
ed with a probability that it will occur (e.g., whether EUS and MRCP will give positive test re-
sults or not). Terminal nodes (triangles) are the decision tree endpoints, beyond which no
further pathways are available. Each terminal node has costs and QALYs associated with it,
summarising the sequence of decisions and events on a unique path from the initial decision
node to that terminal node. These costs and QALYs are expected values, based on the
Fig 1. Decision tree model structure. Description of the decision tree options compared. The nodes are points where more than one event is possible.
Decision nodes (represented by squares) show the different options that might be chosen by decision-makers. Chance nodes (circles) show uncertain
events, each of which is associated with a probability that it will occur. The branches are mutually exclusive events following each node. Terminal nodes
(triangles) are the decision tree endpoints, beyond which no further pathways are available. CBDS = common bile duct stones. EUS = Endoscopic
ultrasound. MRCP = magnetic resonance cholangiopancreatography. ERCP = endoscopic retrograde cholangiopancreatography. c = complications.
doi:10.1371/journal.pone.0121699.g001
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Patients suitable for EUS or MRCP with no contraindications for endoscopic clearance of
CBD stones enter the model at risk of or suspected to have CBD stones. This may be with or
without prior diagnosis of cholelithiasis, with or without symptoms of CBD stones, with or
without prior treatment for CBD stones, and before or after cholecystectomy. The model as-
sumes that patients undergo EUS or MRCP as a diagnostic test followed by ERCP if the test in-
dicates the presence of CBD stones. If CBD stones are confirmed by ERCP then the stones are
removed during the same procedure following endoscopic sphincterotomy (ES) (called thera-
peutic ERCP). If stones are absent then ERCP was diagnostic only (diagnostic ERCP). If thera-
peutic ERCP is unsuccessful in clearing stones endoscopically, patients undergo a second
attempt at endoscopic clearance with therapeutic ERCP, failing which they undergo open cho-
ledochotomy to remove the stones. If CBD stones are present but not detected by EUS or
MRCP (false negatives) then patients may or may not subsequently develop biliary symptoms;
if they do, they will undergo ERCP and ES. If EUS or MRCP do not provide sufficient diagnos-
tic information (e.g. due to patient intolerance of the procedure or technical factors such as
presence of a pacemaker), it is assumed patients undergo the other test (i.e. EUS in patients
who cannot undergo MRCP, MRCP in patients who cannot undergo EUS).
For patients proceeding directly to ERCP it is assumed they undergo diagnostic ERCP, and
if CBD stones are present they are removed by therapeutic ERCP or by open choledochotomy
if therapeutic ERCP is unsuccessful after the second attempt. If stones are absent patients un-
dergo diagnostic ERCP only. All procedures other than MRCP may have complications.
Probabilities
The probabilities associated with mutually exclusive events at each chance node were ob-
tained from published sources (S1 Table).[2,21,24,29] The probability that CBD stones were
present (the pre-test probability of CBD stones) was estimated as 0.418, which was the medi-
an pre-test prevalence of CBD stones across the 18 studies in the Cochrane Review (range:
0.144–0.679).[21] This probability was varied in sensitivity analyses, to reflect the extent of
real-life variation.
The Cochrane Review also calculated the sensitivity and specificity of EUS (0.95 (95%CI
0.91–0.97) and (0.97 (95%CI 0.94–0.99)) and MRCP (0.93 (95%CI 0.87–0.96) and 0.96 (95%CI
0.900.98)).[21] The model assumes the sensitivity and specificity of direct ERCP were both 1.
The probability of successful endoscopic clearance of stones by therapeutic ERCP was assumed
to be 0.989 based on a systematic review,[2] and the probability of complications with thera-
peutic ERCP (0.187) and open choledochotomy following an unsuccessful first therapeutic
ERCP (0.205) were both taken from another Cochrane Review.[29] A UK audit of ERCP found
success rates of 60–70%; the impact of this is investigated in sensitivity analyses.[30] The prob-
ability of complications associated with diagnostic ERCP (0.055) was taken from a systematic
review and meta-analysis incorporating an economic evaluation.[24] The model also accounts
for the small probability (0.0003) that EUS may result in complications.[31] There are no pub-
lished figures for the probability that diagnostic information is not available from EUS or
MRCP, so we assume a value of 0.01, varying this from 0 to 0.02 in sensitivity analyses. Limited
evidence suggests that asymptomatic bile duct stones may not cause biliary problems.[32]W e
assume the probability such problems will develop in patients where CBD stones are present
but EUS or MRCP give negative results (false negative test results) is 0.01, varying this in
sensitivity analyses.
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QALYs combine length of life and quality of life (the latter measured by utility scores). Utility
scores of 1 and 0 represent full health and death, respectively; negative values represent states
worse than death. A search of the CEA Registry at the Tufts Medical Center was undertaken
using the search term “bile duct stones” [31 August 2013] to identify studies reporting relevant
utility scores.[33] After reviewing the reference lists of identified studies and removing dupli-
cates, four studies containing relevant utility data were identified.[23,25,34–35] Utility scores
for the health states required by the model were taken from one study,[23] selected because
utility scores for all the health states in the model were included in this study enabling better
comparability between values, and because the study reported parameter values that could be
used in sensitivity analyses (S1 Table). No published studies were found that reported on the
duration of each event in the decision tree so all assumptions were based on clinical opinion
and varied in sensitivity analysis (S1 Table). The duration of each pathway in the decision tree
was calculated by summing the duration of each event in that pathway. Patients were assumed
to be in full health (i.e. a utility of 1) during the period from the end of the pathway up to 12
months (the time horizon of the model).
Costs
The costs of EUS with and without complications were assumed to be $1336 and $803 respec-
tively, and the cost of MRCP was assumed to be $356 (S1 Table).[36] The cost of EUS is the av-
erage value of the national mean cost of diagnostic endoscopic upper gastrointestinal tract
procedures performed on an elective inpatient and day case basis in the UK, weighted by the
proportion of patients in each group. The cost of MRCP ($356) is the average value of the na-
tional mean cost of magnetic resonance imaging scans for two to three areas, with contrast,
performed either on an outpatient basis or as direct access, weighted by the proportion of pa-
tients in each group. Diagnostic ERCP was assumed to cost $5601 with complications and
$1149 without complications; therapeutic ERCP was assumed to cost $5601 with complications
and $1412 without complications.[36] Open choledochotomy was assumed to cost $7794 and
$6503 with and without complications.[36] The model accounts for the probability (0.023)
that therapeutic ERCP may require a second procedure to successfully remove the CBD stones.
[2]
Measuring cost-effectiveness
Cost-effectiveness was measured using monetary net benefits (MNBs). For each treatment the
MNB was calculated as the mean QALYs per patient accruing to that treatment multiplied by
decision-makers’ maximum willingness to pay for a QALY (also referred to as the cost-effec-
tiveness threshold) minus the mean cost per patient for the treatment. In the UK the lower and
upper limit of the maximum willingness to pay for a QALY are £20,000 ($29,000) and £30,000
($43,000) respectively.[37] This approach converts the outcomes from each treatment into
monetary terms and then subtracts the costs of each treatment from the monetised benefits,
calculating the net benefit of each treatment in monetary terms. MNBs were calculated using
the base case parameter values (S1 Table); these are referred to as deterministic results since
they do not depend on chance. The option with the highest MNB represents good value for
money and is preferred on cost-effectiveness grounds.
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One-way sensitivity analysis was undertaken, varying the probabilities, outcomes and costs one
at a time within the ranges in S1. The aim was to identify the values where each option (EUS,
MRCP, direct ERCP) had the highest MNB. We undertook a further univariate sensitivity anal-
ysis in which the probability of developing biliary symptoms where CBD stones are present but
EUS or MRCP give (false) negative results was allowed to vary separately for EUS and MRCP
between 0 and 1.
We also undertook a probabilistic sensitivity analysis (PSA).[38] Distributions were as-
signed to parameters (S1 Table) to reflect the uncertainty with each parameter value. A random
value from the corresponding distribution for each parameter was selected. This generated an
estimate of the mean cost and QALYs and the MNB associated with each treatment. This was
repeated 5000 times and the results for each simulation were noted. The mean value for each
model parameter and the mean MNB for each treatment was calculated from the 5000 simula-
tions; these are referred to as probabilistic results since they depend on chance. Using the
MNBs for each of the 5000 simulations, the proportion of times each treatment had the highest
MNB was calculated for a range of values for the maximum willingness to pay for a QALY.
These were summarised graphically using cost-effectiveness acceptability curves.[27]
In the PSA, beta distributions were used to model uncertainty in probabilities and utility
scores, and gamma distributions to model uncertainty in costs (S1 Table).[38] Uniform distri-
butions were used where the base case value was based on assumption, and for the probability
of complications with EUS, which was reported in a single secondary data source containing a
point estimate but no measure of uncertainty.[31] Where standard errors were required for the
PSA but not reported, it was assumed these were equal to the mean.[38] For the probability
that CBD stones were present (the pre-test probability of CBD stones), the parameter values
for the beta distribution were based on the total numbers of patients with and without CBD
stones pooled across all studies in the Cochrane Review. The parameter values for the sensitivi-
ty and specificity of EUS and MRCP were calculated from the 95% confidence intervals re-
ported in the Cochrane Review.[21] The 95% confidence intervals around the base case values
were derived using standard deviations calculated from the 5000 simulations in the PSA.
Results
Using base case values, diagnosing and treating CBD stones using MRCP to select patients for
ERCP was significantly less costly than using EUS to select patients or proceeding directly to
invasive testing by ERCP ($1299 versus $1753 and $1781, respectively). Similar QALYs were
accrued by each option (0.998, 0.998 and 0.997 for EUS, MRCP and direct ERCP, respectively)
(Table 1). MRCP produced the same QALYs as EUS, but was less costly due to lower test costs
($356 versus $803). Using EUS or MRCP to select patients for ERCP produced negligibly more
QALYs than direct ERCP because the negative impact on utility of invasive testing in patients
who did not have CBD stones was avoided, but only for a short period of time. The MNB was
significantly higher for MRCP compared with the other two options at a maximum willingness
to pay for a QALY of $29,000 and $43,000, indicating that MRCP was preferred on cost-effec-
tiveness grounds using base case values. As expected, the probabilistic MNBs were numerically
similar to the deterministic MNBs (not shown).
In the one-way sensitivity analysis the results were not sensitive to changing the base case
values within the stated ranges. MRCP had the highest MNB in all situations. When the proba-
bility of developing biliary symptoms where CBD stones are present but EUS or MRCP give
negative results was allowed to vary from 0 to 1 separately for both EUS and MRCP, MRCP al-
ways had the highest MNB.
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probability of being cost-effective at a maximum willingness to pay for a QALY of $29,000 and
a 61.1% probability at a value of $43,000 (Fig. 2). For EUS the values were 25.2% and 25.3%, re-
spectively. For direct ERCP they were 13.9% and 13.6%, respectively.
Table 1. Base case results.
EUS MRCP Direct ERCP
Costs (US$) 1,753 (1,692, 1,814) 1,299 (1,256, 1,342) 1,781 (1,724, 1,838)
QALYs 0.998 (0.998, 0.998) 0.998 (0.998, 0.998) 0.997 (0.997, 0.997)
Monetary net beneﬁt
$29,000 27,164 (27,103, 27,225) 27,616 (27,573, 27,660) 27,118 (27,061, 27,175)
$43,000 41,622 (41,561, 41,683) 42,074 (42,031, 42,117) 41,568 (41,511, 41,624)
EUS = Endoscopic ultrasound. MRCP = magnetic resonance cholangiopancreatography.
ERCP = endoscopic retrograde cholangiopancreatography. QALY = quality adjusted life year.
Costs are in 2011/12 US$. Figures are expected values per patient with 95% conﬁdence intervals in
brackets. The point estimates are calculated using base case values of the model parameters
(deterministic results). The 95% conﬁdence intervals are derived using standard deviations calculated from
the 5000 simulations in the probabilistic sensitivity analysis. The monetary net beneﬁt is calculated at a
maximum willingness to pay for a QALY of $29,000 and $43,000. Numbers may not sum due to rounding.
doi:10.1371/journal.pone.0121699.t001
Fig 2. Cost-effectiveness acceptability curves at different values of the maximum willingness to pay
for a QALY. Results from the cost-effectiveness acceptability analysis. MRCP had a 61.0% probability of
being cost-effective at a maximum willingness to pay for a QALY of $29,000 and a 61.1% probability at a
value of $43,000. For EUS the values were 25.2% and 25.3%, respectively. For direct ERCP they were
13.9% and 13.6%, respectively. EUS = Endoscopic ultrasound. MRCP = magnetic resonance
cholangiopancreatography. ERCP = endoscopic retrograde cholangiopancreatography QALY = quality
adjusted life year.
doi:10.1371/journal.pone.0121699.g002
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Main findings
This study compares the cost-effectiveness of using EUS or MRCP to select patients for ERCP
in patients with suspected CBD stones as opposed to proceeding directly to ERCP. Initial
MRCP was the most cost-effective option. It was significantly cheaper than EUS and invasive
testing by ERCP. MRCP was less costly than EUS due to the lower test costs, and was less costly
than direct ERCP because it avoided the costs of invasive testing in patients who did not have
CBD stones. MRCP produced similar QALYs as EUS and proceeding directly to invasive test-
ing by ERCP. EUS and MRCP avoided the utility decrement incurred by direct ERCP associat-
ed with complications of invasive testing in patients who did not have CBD stones, but in the
absence of data the duration of this utility decrement was assumed to be small so similar
QALYs were achieved by the three options. MRCP produced the same QALYs as EUS due to
their similar sensitivity and specificity.[21] The MNBs for MRCP were significantly higher
than those for EUS and ERCP at a maximum willingness to pay for a QALY of $29,000 and
$43,000.
Strengths and weaknesses
A strength of this study is that it was based on a recently published Cochrane Review that ana-
lysed in detail available evidence for the diagnostic accuracy of EUS and MRCP in patients
with suspected CBD stones.[21] An extensive sensitivity analysis was performed, which showed
little variation in the findings.
There are some weaknesses. First, due to lack of data, the model makes assumptions con-
cerning the probability that EUS and MRCP do not provide diagnostic information, the proba-
bility of subsequent biliary symptoms in false negative cases where CBD stones have been
missed by EUS and MRCP, and the duration of events. The model assumes an overall pretest
probability of 41.8% for the presence of CBD stones. In practice, clinicians will use clinical
judgement to refine their pretest estimate of CBD stones based on lab values, patient symp-
toms, so the subsequent sequence of testing is based on their judgement. In one way sensitivity
analysis, our results were not sensitive to varying this probability within reasonable limits. The
assumed values were tested in sensitivity analyses, and varying them did not alter the conclu-
sions. Second, the model assumes the probability of successful endoscopic clearance by thera-
peutic ERCP following MRCP and EUS is the same, whereas the success rate may be higher
following MRCP due to the extra information that it provides for the endoscopist about the
anatomy of the biliary tree. There is no evidence to justify such a difference, but if this was the
case then it would produce stronger findings in support of MRCP. Third, the model assumes
the sensitivity and specificity of direct ERCP were both 1. ERCP is the best available test for
confirmation but can misclassify the presence or absence of CBD stones.[39] While ERCP may
not be 100% accurate, this is a conservative estimate to evaluate the incremental costs and ben-
efits of using EUS or MRCP to select patients for ERCP against proceeding directly to ERCP. If
a sensitivity and specificity less than 1 were assumed this would make both EUS and MRCP ap-
pear more cost-effective compared with direct ERCP, and would not affect the relative cost-ef-
fectiveness of MRCP compared with EUS. Fourth, ERCP is associated with a small risk of
mortality, which has not been accounted for in the model.[40] If a small mortality risk with
ERCP was assumed then EUS and MRCP would appear more cost-effective, and given the sim-
ilarities between EUS and MRCP, their relative cost-effectiveness would not be affected. Fifth,
this cost-effectiveness model is based on patients with suspected common bile duct stones
using data from a systematic review which specifically assessed the role of EUS and MRCP in
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view had gallstones or had previously undergone cholecystectomy for gallstones. Thus, the
findings of this study are applicable only for such patients and not in people with suspected
malignant obstructive jaundice. Consequently, we have not modelled the impact of missed di-
agnosis of malignancy in this research. Finally, the scope of this study encompasses the direct
benefits and harms of MRCP and EUS in imaging CBD only. There may be other practical ben-
efits of these modalities which would impact on their cost-effectiveness. For example, MRCP
may be helpful in detecting other incidental soft tissue lesions. EUS will give information on
the pancreas, perigastric and mediastinal regions which may inform management of the patient
beyond CBD. Similarly it does not consider the costs of anaesthesia required in most cases for
EUS. Factoring costs if anaesthesia associated with EUS into the model would further increase
the cost-effectiveness of MRCP.
Comparison with other studies
Consistent with previous studies this study finds that initial MRCP or EUS to select patients
for ERCP are cost-effective compared with direct ERCP.[23–26] Unlike other studies results in
this study are not sensitive to varying the probability that CBD stones were present.[23,26]
Implications for policy and practice
In the UK MRCP should be used rather than EUS to select patients for ERCP in patients with
suspected CBD stones.
The cost saving per patient found in this study could translate to $9.7 million per year for
the NHS if MRCP was widely adopted to diagnose CBD stones and select patients for ERCP
rather than EUS. This estimate assumes 32,300 cases of suspected CBD stones each year (based
on 50 million adults in the UK,[41] a prevalence of gallstones of 15%,[21] that 2% of gallstones
are symptomatic each year,[42] that 9% of these are due to CBD stones,[43–45] and a pre-test
probability of CBD stones of 0.418]. [21] There is no evidence on the use of EUS versus MRCP
to diagnose CBD stones in the UK[46] but if 50% of CBD stones are already diagnosed using
MRCP and 50% are diagnosed using EUS then the cost saving would still be $4.8 million.[39]
Further research
Further research is needed to evaluate the probability of inconclusive test results with EUS and
MRCP, and to evaluate the management of false negative cases following EUS and MRCP.
The generalizability of these results to healthcare settings outside the UK depends on the
costs of EUS and MRCP. In the UK these were $1336 and $356 respectively. Our findings were
not sensitive to the costs of these tests, but further research taking account of the relative costs
of these modalities outside the UK will be needed to assess generalizability.
It is likely that local availability of these modalities is a major determinant of use and limited
availability could affect cost-effectiveness. MRCP is available in most hospitals, but there may
be limited access outside working hours. If waiting for available MRCP results in patients need-
ing an extra night of hospital care, this would increase the costs of this modality. In contrast, if
EUS is available immediately, the endoscopist could conduct EUS initially and if positive, pro-
ceed with ERCP in the same setting, which could reduce its costs. Further research would be
beneficial to explore the cost-effectiveness of improving access to MRCP.
The population expected value of perfect information (EVPI) is a measure of the maximum
that the healthcare system should be willing to pay for additional research to reduce uncertain-
ty. The EVPI is the difference between the maximum expected net benefit based on perfect in-
formation and based on current knowledge, multiplied by the size of the population that could
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in the UK each year, a time horizon of 10 years and a discount rate of 3.5%,[36] the EVPI was
estimated to be $25.5 million at a maximum willingness to pay for a QALY of $29,000-$43,000.
This is comparable with the EVPI calculated in a comparison of early versus delayed laparo-
scopic cholecystectomy for acute cholecystitis ($39.4-$82.9 million).[47]
Conclusion
From the perspective of the UK NHS, MRCP was the most cost-effective test in the diagnosis
of CBD stones.
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